Rivaroxaban in clinical practice for atrial fibrillation with special reference to prothrombin time.
BACKGROUND
Prothrombin time (PT) distribution in Japanese nonvalvular atrial fibrillation (NVAF) patients under rivaroxaban therapy remains to be clarified.


RESULTS
Between May 2012 and July 2013, 115 NVAF patients received rivaroxaban (PT was measured in 94; reagent: recombiplastin). In these patients, (1) PT values were distributed widely from patient to patient and from peak to trough, (2) the time-dependence was obscure with sampling at any time in the outpatient clinic, and (3) the incidence of adverse events was too low for analyzing the relation with PT.


CONCLUSIONS
We report the distribution of PT for Japanese NVAF patients under rivaroxaban therapy in real-world clinical practice.
Department of Cardiovascular Medicine, The Cardiovascular Institute.
Shinya
S
Suzuki
Takayuki
T
Otsuka
Koichi
K
Sagara
Hiroto
H
Kano
Shunsuke
S
Matsuno
Yuko
Y
Kato
Hideaki
H
Takai
Tokuhisa
T
Uejima
Yuji
Y
Oikawa
Kazuyuki
K
Nagashima
Hajime
H
Kirigaya
Junji
J
Yajima
Hitoshi
H
Sawada
Tadanori
T
Aizawa
Takeshi
T
Yamashita
D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People; D001281:Atrial Fibrillation / Q000097:blood* / Q000188:drug therapy*; D065427:Factor Xa Inhibitors / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage*; D011446:Prospective Studies; D011517:Prothrombin Time; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage*
D065427:Factor Xa Inhibitors; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban